Premium
Case Report: Transitioning to a Mixed‐Oil Intravenous Lipid Emulsion in an Adult Patient Receiving Home Parenteral Nutrition
Author(s) -
Bathgate Jennifer R.,
Matarese Laura,
Ziegler Jane,
TougerDecker Riva
Publication year - 2020
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1002/ncp.10387
Subject(s) - medicine , parenteral nutrition , fish oil , soybean oil , fat emulsion , emulsion , liver function , liver disease , limiting , surgery , fish <actinopterygii> , biochemistry , mechanical engineering , chemistry , pathology , fishery , engineering , biology
Abstract A potential risk of long‐term parenteral nutrition (PN) is intestinal failure–associated liver disease (IFALD). One recommendation for mitigating risk is limiting the fat dose to reduce the harmful effects of the ω‐6 fatty acids, which are the main ingredient in traditional fats. SMOFlipid (SMOF) (Kabi‐Fresenius, Bad Homburg, Germany) is a combination of soybean oil, medium‐chain triglycerides, olive oil, and fish oil emulsion. This fat source may alleviate the risk of IFALD and improve liver function tests. A patient with a long history of PN reliance and IFALD is presented in this case report. After 4 months on SMOF, total and direct bilirubin levels improved.